课题基金 / 基金详情

THE GENE FOR HUMAN BETA GALACTOSIDASE-A

THE GENE FOR HUMAN BETA GALACTOSIDASE-A
人类 β 半乳糖苷酶-A 基因
批准号:
6271626
负责人:
DAVID CALHOUN
金额:
$3.01万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
1997
资助国家:
美国
项目状态:
已结题
起止时间:
1997-02-01 至 1999-01-31

项目摘要

项目成果

DAVID CALHOUN的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
The first objective of this research is to analyze the promoter of the alpha-galactosidase A gene in order to investigate the factors that control the expression of this gene in particular, and of this class of genes in general. The levels of lysosomal enzymes are known to vary widely, at least in rodents, during organ development and during changes in the number of lysosomes within a given cell. Antigenic stimulation of immune cells results in a dramatic increase in lysosomal enzyme levels. It is not known if these changes occur at the level of transcription or posttranscriptionally. In addition, mechanisms exist to coordinately regulate the levels of this class of enzymes, since the relative ration of one enzyme to another remains relatively constant, although the absolute levels of the enzymes may vary widely. We have recently isolated a genomic clone containing the promoter for the human alpha-galactosidase A, which is the first genomic clone isolated to date for any lysomal hydrolase, and it should be valuable for the proposed studies of gene regulation. The second objective of this research is to pursue the development of one possible strategy for the treatment of Fabry disease, a prototype inherited metabolic disorder. Previous studies have demonstrated the ability of exogenous alpha-galactosidase A to correct the metabolic defect in Fabry fibroblasts, and clinical trials have suggested the potential effectiveness of enzyme replacement. Human alpha-galactosidase A produced in bacteria, yeasts, and baculovirus will be evaluated using a cell culture system for enzyme replacement in Fabry disease. The cloned cDNA for alpha-galactosidase A will be introduced into Fabry cells in culture to monitor its integration and expression.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
AREA I BIOMOLECULAR STRUCTURE & FUNCTION: AIDS
  • 批准号:
    8166246
  • 项目类别:
  • 资助金额:
    $63.11万
  • 财政年份:
    2009
  • 负责人:
    DAVID CALHOUN
  • 依托单位:
AREA I BIOMOLECULAR STRUCTURE & FUNCTION: AIDS
  • 批准号:
    7959166
  • 项目类别:
  • 资助金额:
    $72.27万
  • 财政年份:
    2009
  • 负责人:
    DAVID CALHOUN
  • 依托单位:
AREA I BIOMOLECULAR STRUCTURE & FUNCTION: AIDS
  • 批准号:
    7715272
  • 项目类别:
  • 资助金额:
    $27.57万
  • 财政年份:
    2008
  • 负责人:
    DAVID CALHOUN
  • 依托单位:
AREA I BIOMOLECULAR STRUCTURE & FUNCTION: AIDS
  • 批准号:
    7561533
  • 项目类别:
  • 资助金额:
    $38.4万
  • 财政年份:
    2007
  • 负责人:
    DAVID CALHOUN
  • 依托单位:
国内基金
海外基金
asr基因调控酸诱导的Escherichia coli O157:H7形成VBNC状态的机制研究
  • 批准号:
    32302245
  • 项目类别:
    青年科学基金项目
  • 资助金额:
    30.00万元
  • 批准年份:
    2023
  • 负责人:
    潘寒姁
  • 依托单位:
小肠中Escherichia coli分泌细菌毒素诱导肠屏障损伤及细菌易位在炎症性肠病中的机制研究
  • 批准号:
    82371775
  • 项目类别:
    面上项目
  • 资助金额:
    46万元
  • 批准年份:
    2023
  • 负责人:
    朱慧媛
  • 依托单位:
基于Escherichia coli O157:H7亚致死态细胞探究超高压与原儿茶酸协同杀菌机制
  • 批准号:
    31871817
  • 项目类别:
    面上项目
  • 资助金额:
    60.0万元
  • 批准年份:
    2018
  • 负责人:
    孙爱东
  • 依托单位:
肠肝轴:从临床患者分离的肠道致病菌株Escherichia coli NF73-1对非酒精性脂肪性肝病的作用及机制研究
  • 批准号:
    81873549
  • 项目类别:
    面上项目
  • 资助金额:
    57.0万元
  • 批准年份:
    2018
  • 负责人:
    刘玉兰
  • 依托单位: